Introducing biosimilar competition for cell and gene therapy products.

Canter B, Sussman S, Colvill S, Arad N, Staton E, Rai A

DOI: 10.1093/jlb/lsae015
Published: 2024 Jul-Dec
Container: Journal of law and the biosciences
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/jlb/lsae015,
  title = {Introducing biosimilar competition for cell and gene therapy products.},
  author = {Canter B and Sussman S and Colvill S and Arad N and Staton E and Rai A},
  year = {2024},
  journal = {Journal of law and the biosciences},
  doi = {10.1093/jlb/lsae015},
  url = {https://doi.org/10.1093/jlb/lsae015}
}

RIS

TY  - JOUR
TI  - Introducing biosimilar competition for cell and gene therapy products.
AU  - Canter B
AU  - Sussman S
AU  - Colvill S
AU  - Arad N
AU  - Staton E
AU  - Rai A
PY  - 2024
JO  - Journal of law and the biosciences
DO  - 10.1093/jlb/lsae015
UR  - https://doi.org/10.1093/jlb/lsae015
ER  -

APA

B, C., S, S., S, C., N, A., E, S., & A, R. (2024). Introducing biosimilar competition for cell and gene therapy products.. Journal of law and the biosciences. https://doi.org/10.1093/jlb/lsae015

Source records

pubmed · retrieved 2026-09-27T10:58:12.022Z
europe-pmc · retrieved 2026-09-27T10:58:12.018Z